Aliya Asher

Learn More
OBJECTIVES To determine the safety, pharmacokinetics (PK), and immunogenicity of the recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with multiple sclerosis (MS) with clinical or MRI activity. METHODS In this 20-week, randomized, double-blind, placebo-controlled phase 1b dose-escalation(More)
  • 1